How I treat von Willebrand disease

被引:54
作者
Rodeghiero, Francesco [1 ]
Castaman, Giancarlo [1 ]
Tosetto, Alberto [1 ]
机构
[1] San Bortolo Hosp, Dept Cell Therapy & Hematol, I-36100 Vicenza, Italy
关键词
INHERITED BLEEDING DISORDERS; SEVERE VONWILLEBRAND DISEASE; MENSTRUAL BLOOD-LOSS; EVIDENCE-BASED DIAGNOSIS; CLINICAL MARKERS; PROSPECTIVE MULTICENTER; FACTOR-VIII; TYPE-1; DESMOPRESSIN; MANAGEMENT;
D O I
10.1182/blood-2009-01-153296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent multicenter studies have clarified the molecular basis underlying the different von Willebrand disease (VWD) types, all of which are caused by the deficiency and/ or abnormality of von Willebrand factor (VWF). These studies have suggested a unifying pathophysiologic concept. The diagnosis of VWD, remains difficult because its clinical and laboratory phenotype is very heterogeneous and may overlap with normal subjects. Stringent criteria are therefore required for a clinically useful diagnosis. In this paper, we delineate a practical approach to the diagnosis and treatment of VWD. Our approach is based on the critical importance of a standardized bleeding history that has been condensed into a final bleeding score and a few widely available laboratory tests, such as VWF ristocetin cofactor activity, VWF antigen and factor VIII. This approach would help identify those subjects who will probably benefit from a diagnosis of VWD. The next step involves performing a trial infusion with desmopressin in all patients who fail to exhibit an enhanced responsiveness to ristocetin. On the basis of these results and through a series of illustrative examples, the clinician will be able to select the best approach for the optimal management of VWD, according to the patient's characteristics and clinical circumstances. (Blood. 2009; 114: 1158-1165)
引用
收藏
页码:1158 / 1165
页数:8
相关论文
共 71 条
[1]  
ABILDGAARD CF, 1980, BLOOD, V56, P712
[2]   Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD) [J].
Budde, U. ;
Schneppenheim, R. ;
Eikenboom, J. . ;
Goodeve, A. ;
Will, K. ;
Drewke, E. ;
Castaman, G. ;
Rodeghiero, F. ;
Federici, A. B. ;
Batlle, J. . ;
Perez, A. ;
Meyer, D. ;
Mazurier, C. ;
Goudemand, J. ;
Ingerslev, J. ;
Habart, D. ;
Vorlova, Z. ;
Holmberg, L. ;
Lethagen, S. ;
Pasi, J. ;
Hill, F. ;
Peake, I. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (05) :762-771
[3]   Reduced von Willebrand factor survival in type Vicenza von Willebrand disease [J].
Casonato, A ;
Pontara, E ;
Sartorello, F ;
Cattini, MG ;
Sartori, MT ;
Padrini, R ;
Girolami, A .
BLOOD, 2002, 99 (01) :180-184
[4]  
Castaman G, 1999, THROMB HAEMOSTASIS, V82, P1065
[5]  
Castaman G, 2008, HAEMOPHILIA, V14, P15, DOI 10.1111/j.1365-2516.2007.01606.x
[6]  
Castaman G, 2000, THROMB HAEMOSTASIS, V84, P351
[7]   Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study [J].
Castaman, G. ;
Rodeghiero, F. ;
Tosetto, A. ;
Cappelletti, A. ;
Baudo, F. ;
Eikenboom, J. C. J. ;
Federici, A. B. ;
Lethagen, S. ;
Linari, S. ;
Lusher, J. ;
Nishino, M. ;
Petrini, P. ;
Srivastava, A. ;
Ungerstedt, J. S. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (10) :2164-2169
[8]   Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect [J].
Castaman, G ;
Federici, AB ;
Bernardi, M ;
Moroni, B ;
Bertoncello, K ;
Rodeghiero, F .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :357-360
[9]   Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease [J].
Castaman, G ;
Bertoncello, K ;
Bernardi, M ;
Rodeghiero, F .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) :391-392
[10]  
Castaman G, 2003, HAEMATOLOGICA, V88, P94